• Dementia Currently Affects More than 57 Million People Worldwide, and Numbers are projected to almost triple the Next 25 Years.
  • Many Factors Can increased to Person’s Risk of Developing Dementia, Including Age, Genetics, Vascular Diseases and, According to Newer Research, Sub Viral Infections.
  • One Viral Infection Linked to an Increased Risk of Dementia Is Shingles, Caused When a Dormant Chicken Pox Virus Reactivates In Nerve Cells.
  • New Research Suggests that Vaccination Against Shingles Could Reduce The Risk of Dementia By 20%.
  • If they are findings are verified, Shingles Vaccination Could Be at Cost-Effective Way of Slowing The Rapid Increased in Dementia Cases.

GLOBALLY, THE NUMBER OF PEOPLE AFFECED BY Dementia increase by 117% Between 1990 and 2016, with More than 57 Million People Now affected by the condition. And Numbers are projected to rise to more than 150 million by 2050.

The Centers For Disease Control and Prevention (CDC) Advis That People Can Help Reduces Their Risk of Developing Dementia by Maintaining An Active Lifestyle and Healthy Diet, and Controlling Conditions, Such as Diabetes and High Blood Pressure. However, Sub Risk Factors, Including Age and Genetics, Are Beyond to Perso’s Control.

Research has shown that Viral Infections, particularly That Fect the Nervous System, Are Associated With An Increased Risk of Dementia.

Now, A Study Led By Scientists from Stanford Medicine, Published in Natureyou have demonstrated that vaccination against saling, which occurs when the Varicella Zoster virus Reactivates Subime AFTER INITIAL INFECTION, COULD Decree Dementia Risk by As 20%.

The Refectchers Suggest This provides Further Evidence of the Link Between Viral Infection and Dementia, and That the Vaccine Could Be at Cost-Effective Way of Rasting the Risk of Dementia.

Courtney M. Kloske, PHD, Alzheimer’s Association Director of Scientific engagement, not involved in This Study, commented for Medical News Today That:

“This new study adds to Our Current Knowledge by Suggesting The Shingles Vaccine May Also Reduces SuboSe’s Risk of Developing Dementia. BeSe New Results, While Preliminary, Call for Further Studies In Large, Diverse Study Populations to inform you WHETHER VACCINATIONS CAN DECREASE OUR RISK OF DEVELOPING DEMENTIA AS WE AGE. ”

Strongest Evidence Yet on Dementia and Shingles

The Study Took Advantage of a Health Policy In Wales Which, on Septent 1, 2013, Introduced The Shingles Vaccine, Using A Live-Attenuated (Weakened) form of the virus.

The Health Authority offered the Vaccine to All 79-Yare-Olds (Born on Or After Sepcess 1, 1933), But Anyone Born Before September 1, 1933 was not choosed.

By Selecting Thoso Born One Week Eithher Side of Septmber 1, 1933, The Refers Had Two Age-Matched Groups of People, One of Which Had Received The Shingles Vaccine and One Which Had Not.

Senior Author on the Study, Pascal Geldsetzer, MD, PHD, MPH, Assistant Professor of Medicine at Stanford University, Said in a Press Release that ” Little Bit Too Old To Be Eligible for The Vaccine – and an Intervention Group – Host Just Young Enough To Be Choose. ”

The Refers Compare The Health Outcomes of Both Groups for the Next 7 Years. ABOUT HALF OF THOSE Choose for The Vaccine Received It, Combine with Almost of Those Not Eligible. In Their Analysis, They Allowed for the Fact that not Everyone Was Choose for the Vaccine Received It.

During the 7 Year Follow Up, of the 296,324 People in the Sample, 14,465 Had at Least One Diagnosis of Shingles. Those Who Had Received The Vaccine Had at 37.2% Lower Relative Risk of Getting Shingles Than Those were unvaccinated.

In This Study, The Refers Did Not Differentiate Between Different Types of Dementia. A person was remembered as having dementia if there was a new diagnosis of dementia in the electronic Health Record Data, or If Dementia was listed on their Death certifies as a primary or contributory cause of death.

SHINGLES VACCINE Redmery Risk by 20%

A Total of 35,307 People Were Newly Diagnosed with Dementia During the 7-Year Follow-up period.

Of these, People Who Had Received The Shingles Vaccine Were 3.5% Less Likely To Relevance A Dementia Diagnosis, which corresponds to a relative reduction of 20%.

Steven Allder, MD, Consultant Neurologist at Re: Cognition Health, Not Involved in This Research, Told MNT That:

“The Findings Strengthen the Case for finding Shingles Vaccination in Older Adults. If Further Research Confirms The Link Between The Vaccine and Lower Dementia Risk, It Could Make Vaccination An Even More Complia Public Health Strategy. Given The High Economic and Social Costs of Dementia Care, to relativley exceptively vaccine could provided to be at Cost-Effective Preventive Measure. “

Women See The Greatest Dementia Risk Reduction

The Effect of the Vaccination on Dementia Risk Difference Markedly Between The Sexes, With A Much Greater Reduction in New Diagnose of Dementia in Women Than Men.

This was seen the vaccination having similar Effects on DiagniS of Shingles and Postherpetic Neuralgia – Chronic Nerve Pain That Can Last Up To Several Months After Shingles – In Both Men and Women.

“This could be due to biological differences in immune responsibility Between Men and Women,” Allder Sug forest.

“Women Generally has stroger immune reactions to Vaccines, which might lead to a greater protection effect.

Shingles Vaccine: A Cost-Effective Way to Prevent or Dementia?

In the United States, The CDC Recommend the Shingles Vaccination, Shingrix, for Tose Anged 50 or Over, and For Anyone Over The Age of 19 with a Weakened Immune System.

Medicare or insurance may cover all or part of it. Generally in the US, The Vaccine Costs Around $ 400 for the 2-Give Course. According to the CDC, The Vaccine Is Not Associated with Any Severe Adverse Events, and is over 90% Effective in Preventing Shingles.

In the United Kingdom, The Shingles Vaccine Is Provided Free By The National Health Service (NHS) to People Between The Ages of 60 and 80 and Host Who Are Immunocompromised. EACH DOSE OF THE 2-DOSE COURSE THE NHS £ 160. It is also available privately, costing around £ 460 for two doses.

The Refectchers Who Driving The Current Study Suggest that If Further Research Verifies Their Findings, The Shingles Vaccine Could Be A Much More Cost-Effective Way To Prevent or Delay The Condition The Existing Pharmaceutical Interventions.

Do Current Shingles Vaccines Yield The Same Protective Effect?

Nevertheless, Sub Key Questions Remain in Place.

The Current Study Assessed Dementia Risk in People Who Had Received The Older Vaccine, which used live-attanuated form of the virus. SHINGRIX IS A RECOMBINANT ZOSTER VACCINE.

David Cutler, MD, Board-Certified Family Medicine Physician At Providence Saint John’s Health Center in Santa Monica, CA, Not Involved in the Research, Urged Sub Caution About the Findings.

CUTLER ASKED: “If the effort on Dementia was real, was it ow to the vaccine or was it due to the loower incidents of scam in the study population?”

“Clearly The Zostavax Vaccine was Effective at Preventing Shingles. However,” I have cautnted, “That Vaccine Is No Longer Available in the United States. Instead, We have the Much More Effective Shingrix Vaccine.”

“Until A Study is done comparising the zostavax and shingrix vaccines, Involving Thousands of People Over Many Years (Vray Costly, and Unlikely to Oscur) it won’t be Known if the shingix Vaccine Will Yield comparable Effects,” He To Told MNT.

According to Allder:

“While This Study Provides Strong Evidence of a Link Between Shingles Vaccination and Lower Dementia Risk, A Randomized Controlled Trial Woubed Be Needed To establish a definitive causal define Vaccines Might Play a Role in Preventing Neurodegenerative Diseases. “

CUTLER AGREED. “For Now, a good take home point is that sharingles are Effective for Preventing Shingles, which is inquater reason for getting This Vaccine If you are choosing.

However, He Added That: “This Protection Is Far from Assured. SO (…) The other Known Means of Preventing Cognitive Decline As We Age Should Still Be Pursued.”